摘要
目的评价阿立哌唑与奎硫平治疗首发精神分裂症的疗效和安全性。方法将90例首发精神分裂症患者随机分为阿立哌唑组及奎硫平组进行治疗,分别在治疗前及治疗2,4,6,8周末采用阳性与阴性症状量表(PANSS)评定临床疗效,用不良反应症状量表(TESS)评定药物不良反应。结果阿立哌唑能有效治疗首发精神分裂症的阳性症状及阴性症状,疗效与奎硫平相当,不良反应较奎硫平更少。结论阿立哌唑是一种有效而安全的新型抗精神病药。
Objective To evaluate efficacy and safety of aripiprazole and quetiapine in the treatment of schizophrenia. Methods A total of 90 patients with first episode schizophrenia were randomly divided into aripiprazole group and quetiapine group. Positive and negative symptom scale （PANSS） and treatment emergent symptom scale（TESS） were used to evaluate the efficacy and adverse events of drugs before and after 2,4,6,8 weeks of treatments. Results Aripiprazole had similar effects to quetiapine in the treatment of schizophrenia with positive and negative symptoms, with fewer side effects. Conclusion Aripiprazole is one of effective and safe drugs in the treatment of schizophrenia.
出处
《中国健康心理学杂志》
2009年第11期1299-1300,共2页
China Journal of Health Psychology
